Core B: TCP: Translational Pathology Core

项目总结-翻译病理学核心 卵巢癌的高病死率使得转化研究对于推进治疗至关重要， 改善成果。希尔曼癌症中心（HCC）卵巢癌（OvCa）孢子翻译 病理学核心（TPC）将提供四个关键服务，以促进创新的转化研究：（1）采购 质量控制、病理学审查和临床注释的生物标本，（2）提取、处理和 存储可以容易地与其他数据类型集成的去识别临床数据（例如，基因型，组学， 元数据），（3）安全共享生物标本和数据，以及（4）开发患者来源的肿瘤模型， 治疗和机制研究。TPC为HCC OvCa SPORE提供这些关键服务 研究人员，其他NCI-funded OvCa SPORE，以及更大的OvCa研究社区。的强度 TPC是OvCa孢子生物储存库，作为先前P50奖项的一部分建立，以支持 OvCa研究人员的翻译需求。生物储存库使所有在HCC妇科就诊的人 宾夕法尼亚州西南部的癌症诊所捐赠样本。癌症患者提供肿瘤、腹水、盆腔 洗涤液、血液、粪便和/或组织样本，用于新鲜或保存的分配。样本纵向 收集的样本包括治疗前、整个临床护理过程中以及项目特定的 时间点。所有标本均接受中心病理学审查。TPC的一个新方面是使用主要患者 组织来生成临床前模型，以促进基础科学和临床前研究。TPC银行单活 细胞肿瘤悬液、分离和扩增原发性患者肿瘤来源的癌症相关间充质细胞 干细胞，并创建混合细胞培养肿瘤类器官。原发性肿瘤也用于产生患者- 衍生的肿瘤异种移植物（PDX），包括新的人源化基质PDX（HS-PDX）。HS-PDX可以是 在具有人源化骨髓的小鼠中产生，以包括人免疫系统。TPC将确保所有 它收集的样本附有注释，将允许将实验室分析与临床分析联系起来。 结果数据和注释将存储在OvCa SPORE数据库中，并将进行更新和检索 研究项目遵循既定的HIPAA协议。TPC利用现有资源 通过HCC，包括癌症中心支持补助金（CCSG）核心和Magee妇女研究 研究所和基金会。因此，它有效地提供并促进了对 支持OvCa SPORE研究者的临床来源数据和生物标本，以及更大的卵巢 癌症研究社区，最终改善患有这种毁灭性疾病的患者的生活。

PROJECT SUMMARY – TRANSLATIONAL PATHOLOGY CORE The high case-fatality of ovarian cancer makes translational studies essential for advancing treatment and improving outcomes. The Hillman Cancer Center (HCC) Ovarian Cancer (OvCa) SPORE Translational Pathology Core (TPC) will provide four key services to facilitate innovative translational studies: (1) procuring quality-controlled, pathology-reviewed, and clinically-annotated biospecimens, (2) extracting, processing, and storing de-identified clinical data that can be easily integrated with other data types (e.g., genotype, omics, metadata), (3) securely sharing biospecimens and data, and (4) developing patient-derived tumor models for therapeutic and mechanistic studies. The TPC provides these critical services to HCC OvCa SPORE investigators, other NCI-funded OvCa SPOREs, and the greater OvCa research community. A strength of the TPC is the OvCa SPORE Biorepository, established as a part of a previous P50 award to support the translational needs of OvCa researchers. The biorepository enables all persons seen at HCC gynecologic cancer clinics in southwestern PA to donate samples. Consented individuals provide tumor, ascites, pelvic washes, blood, stool, and/or tissue samples for fresh or preserved disbursement. Specimens are longitudinally collected to include samples prior to treatment, throughout the course of clinical care, and at project-specific timepoints. All specimens undergo central pathology review. A novel aspect of the TPC is using primary patient tissues to generate preclinical models to facilitate basic science and preclinical studies. TPC banks single live cell tumor suspensions, isolates and expands primary patient tumor-derived cancer-associated mesenchymal stem cells, and creates mixed cell culture tumor organoids. Primary tumor is also used to generate patient- derived tumor xenografts (PDX) including a new humanized stroma PDX (HS-PDX). HS-PDX can be generated in mice with humanized bone marrow to include a human immune system. TPC will ensure that all samples it collects are accompanied by annotations that will permit linking laboratory analyses with clinical results. Data and annotations will be stored in the OvCa SPORE database and will be updated and retrieved for research projects following established HIPAA protocols. The TPC draws on resources already available through HCC, including the Cancer Center Support Grant (CCSG) cores and the Magee-Womens Research Institute and Foundation (MWRI). As such it efficiently and effectively provides and facilitates the testing of clinically derived data and biospecimens to support OvCa SPORE investigators, and the greater ovarian cancer research community, ultimately improving the lives of patients suffering from this devastating disease.